Abstract: In recent years, the incidence rate of intrahepatic cholangiocarcinoma (ICC) has shown an obvious upward trend and the incidence rate of Asian population is higher than that of European and American population, therefore it has drawn more attention in clinical practice. The complexity of characteristics and prognosis of ICC form a great challenge to the treatment of ICC. In order to better guide the diagnosis and treatment of ICC and improve the survival rate of the disease, experts of the Chinese Society of Liver Cancer Cholangiocarcinoma Cooperative Group review the relevant evidence in combination with the actual clinical situation and propose the Chinese expert consensus on management of intrahepatic cholangiocarcinoma (2022 edition). The consensus has focused on the screening and diagnosis, pathological and molecular typing, multidisciplinary diagnosis and treatment surgical therapy, local and systemic therapy of ICC, aiming to improve the ability of clinicians to diagnose and treat ICC, so that patients can obtain the maximum clinical benefit from the treatment.